Mi SciELO
Servicios Personalizados
Articulo
Indicadores
- Citado por SciELO
Links relacionados
- Similares en SciELO
Compartir
Revista de Ciencias Médicas de Pinar del Río
versión On-line ISSN 1561-3194
Resumen
DIA-DIAZ, Antonio Jesús; CONCEPCION-DOMINGUEZ, Ornan; LABRADOR-LABRADOR, Franflin y MARTINEZ-GRAVERAN, Rosa. Application of autologous stem cells in patients with grade IV atherosclerosis obliterans. Rev Ciencias Médicas [online]. 2022, vol.26, n.3 Epub 01-Mayo-2022. ISSN 1561-3194.
Introduction:
peripheral arterial disease of the lower limbs affects a high percentage of the world population; with autologous stem cells obtained from peripheral blood a greater synthesis of growth factors that induce angiogenesis is achieved.
Objective:
to describe the auto-transplantation of autologous stem cells obtained from peripheral blood in patients with grade IV atherosclerosis obliterans in Pinar del Rio treated during period 2009-2019.
Methods:
a descriptive, longitudinal study was carried out with 296 patients with grade IV atherosclerosis obliterans during the period 2009-2019. Autologous peripheral blood stem cell concentrate was obtained. The cells were analyzed by flow cytometry, where they showed a cell viability of 99,3 %. Stem cell concentrate was injected intramuscularly with a number of cells injected of eight, six and ten. The variables studied were ankle-brachial pressure index at rest, pain-free claudication distance, pain scale assessment and amputation criteria.
Result:
pain relief was observed at four weeks and increase in pain-free claudication distance. Post-treatment angiography showed collateral vessel formation. Amputation criteria were met in 95 cases (32 %) and the limb was saved in 201 patients (68 %). The procedure carried out was not associated with complications.
Conclusion:
the application of autologous peripheral blood stem cells is safe and effective for the treatment of grade IV atherosclerosis obliterans.
Palabras clave : ADULT STEM CELLS; ATHEROSCLEROSIS; CELL- AND TISSUE-BASED THERAPY; IMMUNOTHERAPY, ADOPTIVE.